These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 14974882)

  • 1. [New perspectives in the treatment of rheumatoid arthritis].
    Martín Alcalde E; Cantero Blanco S; Sánchez García FJ; Gómez Castillo JJ
    Farm Hosp; 2003; 27(6):360-70. PubMed ID: 14974882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologics in rheumatoid arthritis.
    Sharma PK; Hota D; Pandhi P
    J Assoc Physicians India; 2004 Mar; 52():231-6. PubMed ID: 15636315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.
    Cohen SB
    Rheum Dis Clin North Am; 2004 May; 30(2):365-80, vii. PubMed ID: 15172046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current management: Management of rheumatic diseases in the era of biological anti-rheumatic drugs.
    Konttinen YT; Seitsalo S; Lehto M; Santavirta S
    Acta Orthop; 2005 Oct; 76(5):614-9. PubMed ID: 16263606
    [No Abstract]   [Full Text] [Related]  

  • 5. Rheumatoid arthritis. New disease-modifying and anti-inflammatory drugs.
    Infante R; Lahita RG
    Geriatrics; 2000 Mar; 55(3):30-2, 35-6, 39-40. PubMed ID: 10732003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report.
    Catrina AI; Trollmo C; af Klint E; Engstrom M; Lampa J; Hermansson Y; Klareskog L; Ulfgren AK
    Arthritis Rheum; 2005 Jan; 52(1):61-72. PubMed ID: 15641091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anakinra: new preparation. Weakly effective in rheumatoid arthritis.
    Prescrire Int; 2004 Apr; 13(70):43-5. PubMed ID: 15148945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [When are "biologics" indicated?].
    MMW Fortschr Med; 2006 Apr; 148(17):10. PubMed ID: 16711479
    [No Abstract]   [Full Text] [Related]  

  • 9. Emerging biologic drugs for the treatment of rheumatoid arthritis.
    Puppo F; Murdaca G; Ghio M; Indiveri F
    Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Biological agents for therapy of rheumatoid arthritis--overview].
    Takeuchi T
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():513-6. PubMed ID: 15799409
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety of extended treatment with anakinra in patients with rheumatoid arthritis.
    Fleischmann RM; Tesser J; Schiff MH; Schechtman J; Burmester GR; Bennett R; Modafferi D; Zhou L; Bell D; Appleton B
    Ann Rheum Dis; 2006 Aug; 65(8):1006-12. PubMed ID: 16396977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.
    Bansback NJ; Ara R; Barkham N; Brennan A; Fraser AD; Conway P; Reynolds A; Emery P
    Rheumatology (Oxford); 2006 Aug; 45(8):1029-38. PubMed ID: 16782734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anakinra for therapy of rheumatoid arthritis].
    Tomoo T; Sumida T
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():534-7. PubMed ID: 15799413
    [No Abstract]   [Full Text] [Related]  

  • 14. The 'alphabet' of rheumatoid arthritis treatment.
    Capriotti T
    Medsurg Nurs; 2004 Dec; 13(6):420-8. PubMed ID: 15714747
    [No Abstract]   [Full Text] [Related]  

  • 15. Optimizing outcomes in rheumatoid arthritis.
    Small RE; Schuna A
    J Am Pharm Assoc (2003); 2003; 43(5 Suppl 1):S16-7. PubMed ID: 14626516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function.
    Ernestam S; Hafström I; Werner S; Carlström K; Tengstrand B
    J Rheumatol; 2007 Jul; 34(7):1451-8. PubMed ID: 17477470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving outcomes in tumour necrosis factor a treatment: comparison of the efficacy of the tumour necrosis factor a blocking agents etanercept and infliximab in patients with active rheumatoid arthritis.
    De Filippis L; Caliri A; Anghelone S; Scibilia G; Lo Gullo R; Bagnato G
    Panminerva Med; 2006 Jun; 48(2):129-35. PubMed ID: 16953150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.
    Buch MH; Bingham SJ; Bejarano V; Bryer D; White J; Reece R; Quinn M; Emery P
    Arthritis Rheum; 2007 Apr; 57(3):448-53. PubMed ID: 17394231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of interleukin-1 in bone resorption in rheumatoid arthritis.
    Strand V; Kavanaugh AF
    Rheumatology (Oxford); 2004 Jun; 43 Suppl 3():iii10-iii16. PubMed ID: 15150427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis.
    Kastbom A; Bratt J; Ernestam S; Lampa J; Padyukov L; Söderkvist P; Skogh T
    Arthritis Rheum; 2007 Feb; 56(2):448-52. PubMed ID: 17265480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.